Navigation Links
Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
Date:5/21/2008

TAMPA, Fla., May 21 /PRNewswire/ -- Romark Laboratories, L.C., a privately-owned biopharmaceutical company, today announced the completion of enrollment into its Phase II clinical trial to evaluate the safety and efficacy of nitazoxanide in combination with standard of care therapy in U.S. patients with chronic hepatitis C genotype 1 who have previously failed to respond to the standard of care therapy (peginterferon and ribavirin). The company expects to announce interim data results at a medical meeting this fall. Romark recently announced the initiation of a Phase II trial of nitazoxanide in treatment-naive patients with chronic hepatitis C infected with genotype 1 (STEALTH C-3).

"Completing enrollment in this Phase II trial is a significant achievement for Romark and an important step in the clinical development of nitazoxanide," stated Marc Ayers, Chief Executive Officer of Romark. "We believe nitazoxanide represents a promising approach to the treatment of hepatitis C for the millions of people who are infected with this serious liver disease."

The study, called STEALTH C-2 (Studies to Evaluate Alinia for Treatment of Hepatitis C), is the second in a series of clinical trials designed to evaluate the safety and efficacy of nitazoxanide tablets in combination with Pegasys(R) (peginterferon alfa-2a) or peginterferon and Copegus(R) (ribavirin) in patients with chronic hepatitis C. STEALTH C-2 is a randomized, double-blind, placebo-controlled trial conducted in the United States in 60 patients with chronic hepatitis C genotype 1, who are non-responders to prior peginterferon and ribavirin therapy. The study is designed to evaluate the effectiveness and safety of nitazoxanide administered 500 mg twice daily for four weeks followed by nitazoxanide plus Pegasys plus Copegus combination therapy for 48 weeks, compared to placebo for four weeks followed by placebo plus Pegasys plus Copegus combination therapy for 48 weeks. Pegasys and Copegus are be
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
2. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
3. Romark Laboratories Raises $18 Million in Institutional Financing
4. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
5. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
6. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
7. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
8. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
9. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
10. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
11. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... less invasive, miniaturized circulatory support technologies that are ... announced that it expects revenues for the fourth ... bringing expected full-year 2013 revenues to approximately $208 ... 87% for 2013 above 2012 reflects the first ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. ... a premier and affordable laser tattoo removal experience with the ... Brandeis, focus is in providing high quality cosmetic services with ... all patients. " Southern California ... regret and patients seeking removal for those unwanted tattoos," said ...
(Date:1/14/2014)... 14, 2014 Animal Emergency Critical Care, a LifeCentre partner ... Virginia is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is ... husband, Dr. Cole Taylor , are avid scuba divers. "As ... oxygen when air is thin," states Dr Barnes. She goes on ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... , ... and adopt lifelong healthy behaviors with Health Enhancement Systems, ( ... , The online program, 5 on 5 ( www.5on5.com ... daily habits wrapped in an exciting basketball tournament format. Participants form teams ...
... CLEVELAND , Jan. 19 PolyOne Corporation ... specialized polymer materials, services and solutions, today announced that it ... Linvatec Arthroscopy Unit. , CONMED is a global healthcare leader ... offers forward-looking technology for a growing range of minimally invasive ...
... cardiologists have found a pouchlike structure inside the heart,s left ... blood clots. About 80 percent of the 700,000-plus strokes ... clots blocking a brain artery. In up to a third ... co-author Dr. Subramaniam Krishnan said the discovery of this left ...
... ... to a larger facility to better serve their customers. , ... Farmingdale, NY (PRWEB) January 19, 2010 -- ... reputation for outstanding customer service, contributed to a rapid growth in sales for the ...
... , NEW YORK , Jan. 19 ... the operating efficiencies and service advantages of technology while reducing ... America (Guardian) , a leading provider of employee benefits for ... its self-service benefits website, Guardian Anytime. , Guardian,s campaign will ...
... University of Helsinki, Finland, and the Paul Scherrer Institute ... of the ligand binding domain of a vascular endothelial ... its ligands (VEGF-C). Cancer cells require access to ... By releasing VEGFs, cancer cells stimulate the surrounding blood ...
Cached Medicine News:Health News:Corporate Teams Score Points for Healthy Eating 2Health News:Corporate Teams Score Points for Healthy Eating 3Health News:PolyOne Receives Supplier Excellence Award from CONMED Linvatec 2Health News:Nutricap Labs Energizes 2010 with Move to More Advanced GMP Certified Facility 2Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 2Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 3Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 4
... Kubtec introduces a breakthrough in specimen radiography. ... provide up to 65,536 shades of gray in ... capture the smallest changes in density that heretofore ... including digital detectors from 2 x 2 to ...
The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...
... is an affordable path to Sonesta ... seat, and back adjustments. Packaged with ... full line of Sonesta add-ons, allowing ... for your needs; complete Sonesta flexibility ...
... The Sonesta 6202 is ... Packaged with our most popular ... equipped for a myriad of ... powerful (yet quiet) motors allow ...
Medicine Products: